Nilotinib serves as a high-affinity tyrosine kinase inhibitor indicated for Philadelphia chromosome-positive chronic myeloid leukemia in Nigeria. The Nilotinib 200 mg Capsule operates as a bypass valve system that directs high-pressure flow to block BCR-ABL protein signals responsible for cancer cell growth. Clinical Constraints and Implications In Nigeria, NAFDAC and other regional bodies like the SAHPRA in South Africa emphasize that therapeutic success depends on molecular monitoring. The primary risk involves QT interval prolongation; therefore, baseline ECGs are mandatory. Logistics as Risk Management The wholesale pharmaceutical company needs to sustain its protective "firewall" system, which separates clinical effectiveness from its supply chain operations. Oddway International handles the business-to-business distribution of Nilotinib Capsules throughout Ghana and Cameroon while ensuring their regulatory documents meet strict B2B requirements.